Anesiva Announces Hillsong United FDA Approval of Supplemental New Drug

Anesiva Announces outline Hillsong United FDA Approval hillsong imparts of Supplemental New Drug Application to ExpandZingo(TM) IndicationSOUTH SAN FRANCISCO, Jan. 9 /PRNewswire-FirstCall/ -- Anesiva, Inc.(Nasdaq: ANSV) today announced that the U.S. Food and Drug Administration(FDA) has approved Anesiva's supplemental New Drug Application (sNDA) toexpand the indication for Zingo(TM) to treat the pain associated with blooddraws to include adults. Zingo (lidocaine hydrochloride monohydrate) powderintradermal injection system was previously approved to treat the painassociated with peripheral IV insertions and blood draws in children three to18 years of age. The notification was received according to PDUFA deadlines.As announced in November 2008, Anesiva ceased Zingo commercial activitiesto focus on the development of Adlea(TM), its novel non-opioid, long-actinganalgesic drug candidate for the management of acute pain following orthopedicsurgeries. Anesiva is seeking to license Zingo as well as the underlying drugdelivery technology and intellectual property.About AnesivaAnesiva, Inc.

seeks to be a leader in the development andcommercialization of novel pharmaceutical products for pain management.Anesiva's lead product candidate is Adlea, a novel small molecule formulationof capsaicin that is currently in development for the management of acute painfollowing orthopedic surgeries hillsong united kingdom come . Adlea has been shown in clinical trials toprovide extended pain relief after only a single administration in multipleindications for site-specific, acute and chronic, moderate-to-severe pain.In December 2008, Anesiva announced that a Phase 3 trial of Adlea achievedits primary efficacy endpoint of reduced post-surgical pain versus placebo(p=0.03) following total knee arthroplasty (TKA, or total knee replacementsurgery) at four to 48 hours after surgery hillsong worship . The trial also met its keysecondary endpoint with Adlea demonstrating a highly significant reduction inopioid medication consumption compared to placebo (p=0.005).The Phase 3 TKA trial, known as ACTIVE-2 (Assessment of highly purifiedCapsaicin To ImproVE pain management after orthopedic surgery), also showedthat Adlea's safety profile of adverse events, wound healing, and woundsensory function were similar to placebo over the study duration.Anesiva is based in South San Francisco, CA hillsong music . For more information, go to StatementsThis press release includes "forward-looking statements" within themeaning of the safe harbor provisions of the United States Private SecuritiesLitigation Reform Act of 1995 blessed hillsongs . Words such as "seek" and similar expressionsare intended to identify such forward-looking statements. Forward-lookingstatements in this press release include matters that involve known andunknown risks, uncertainties and other factors that may cause actual results,levels of activity, performance or achievements to differ materially fromresults expressed or implied by this press release. Such risk factors include,among others: the nature and extent of additional Adlea clinical trials thatmay be required by the FDA prior to Anesiva's submission of an application forapproval to market Adlea, whether any clinical trials will be successful, andthe ability to identify and successfully complete a strategic transaction forthe assets related to Zingo.

Actual results may differ materially from thosecontained in the forward-looking statements in this press release hillsong united t shirt . Additionalinformation concerning these and other risk factors is contained in Anesiva'sannual report on Form 10-K for the year ended December 31, 2007, and its mostrecent filing on Form 10-Q.SOURCEAnesiva, Inc.Jean-Frederic Viret, Vice President and Chief Financial Officer of Anesiva,Inc., +1-650-624-9600, or hillsong all of the above . VANCOUVER, Jan hillsong look to you . 9 /PRNewswire/ - Sirius Genomics, a developer ofpharmacogenomic tests, announced today that it has signed a collaborativeagreement with the United Kingdom Critical Care Genomics (UKCCG) Group hillsong mighty to save . Theagreement focuses on the continued development of Sirius' pharmacogenomicdiagnostic for responsiveness to recombinant activated Protein C (sold by EliLilly and Company under the trademark Xigris(R))."The UKCCG group is conducting a large genomic association study looking atsevere life-threatening infections and sepsis.

This new collaboration with theUKCCG group will allow Sirius Genomics to significantly advance thedevelopment of our diagnostic by accessing the comprehensive database that theUKCCG group has compiled . We are delighted to be working with the UKCCG groupto further our progress towards the commercialization of our first product,"commented Dr hillsong dvd . Brad Popovich, President and CEO of Sirius Genomics."The collaboration with Sirius Genomics is in direct alignment with ourobjective to disseminate and promote understanding of functional genomics inthe wider intensive care community," stated Professor Charles Hinds, one ofthe Principal Investigators of the UKCCG Group hillsong kids . "We are very excited to beworking with Sirius Genomics on this new collaboration."Financial terms of the agreement were not disclosed.About UKCCG: UKCCG Group is a collaborative consortium composed of multipleinvestigators, collaborators and members throughout the United Kingdomrepresenting more than 35 hospitals . The group's primary objective is toundertake clinical functional genomics research in the critically ill and todevelop related collaborative, laboratory based research projects withscientific colleagues.About Sirius Genomics: Genomics is a drug-enabling company that excels at developingpharmacogenomic (PGx) tests that lead to better patient outcomes throughpersonalized medicine. Sirius' business focus is on generating value throughimproving the safety and effectiveness of pharmaceutical compounds. TheCompany's expert medical and business team correlates patient genetics withclinical outcomes, leading to proprietary and commercially viable PGx productsthat enable better drug treatment.